Taking stock of the drug industry, from the lab to the medicine chestMarch 16, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer STAT+ | Biden administration to fine manufacturers of 27 medicines for price hikes The Biden administration will fine drugmakers who hiked prices faster than the rate of inflation on 27 medications, it announced Wednesday. By Rachel Cohrs STAT+ | Would the federal government defer to states to regulate PBMs? After years of struggling to regulate the drug middlemen that create pharmacy networks, the government could lean on states to rein them in. By John Wilkerson Opinion: Drug developers navigating 'biology's century' need a model. We made one Biopharma R&D productivity has been in steady decline for at least three decades. Reversing this trend will require many interventions. By Brian Finrow and Aleks Engel and Srinivas Akkaraju David Erickson/AP Texas judge hears arguments in lawsuit to pull long-used abortion pill off the market The case could threaten access to the abortion pill mifepristone, used in the most common form of abortion in the U.S. By Sean Murphy and Matthew Perrone — Associated Press West Nile, Lyme, and other diseases are on the rise with climate change. Experts warn the U.S. is not prepared Climate change is widening the range of disease-carrying vectors like ticks and mosquitoes, increasing West Nile, dengue, and Lyme outbreaks. By Sara Van Note More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments